Conference Coverage
Conference Coverage
How to improve diagnosis of HFpEF, common in diabetes
Heart failure with preserved ejection fraction is common in people with type 2 diabetes but is often hard to recognize. Treatments newly proven to...
Conference Coverage
Once-weekly insulin promising in phase 3 trial in type 2 diabetes
Novo Nordisk’s insulin icodec was superior in lowering A1c compared with daily degludec without increasing the risk for moderate or severe...
Conference Coverage
Ezetimibe-statin combo lowers liver fat in open-label trial
A significant 5.8% decrease in hepatic steatosis was seen after 24 weeks’ treatment with ezetimibe and rosuvastatin comparing baseline with end of...
Conference Coverage
Cre8 EVO stent loses sweet spot in diabetes at 2 years: SUGAR
Outcomes once deemed “almost too good to be true” disappeared with longer follow-up in an all-comer population of patients with diabetes...
Conference Coverage
Emphasis on weight loss in new type 2 diabetes guidance
No major changes but several shifts in emphasis since the last update in 2019, including weight loss as a co–primary goal of management.
Conference Coverage
Unsure on the best T2D drug choice? Let patients decide
Serially testing equally viable drug options for people with type 2 diabetes can identify the regimen that works best for each individual patient...
Conference Coverage
Early age at hysterectomy ups type 2 diabetes risk
Having a hysterectomy appears to increase the risk of incident type 2 diabetes, particularly in younger women, and if the ovaries are removed at...
Conference Coverage
Could cold exposure, especially shivering, combat type 2 diabetes?
"The results are highly promising and may eventually suggest an alternative treatment or preventative measure for type 2 diabetes."
Conference Coverage
Mothers’ diabetes linked to ADHD in their children
A small increased risk of ADHD in children born to mothers with diabetes, including pregestational diabetes and gestational diabetes, has been...
Conference Coverage
Triple threat: Novel agent shows potent T2D weight loss in phase 1
A novel triple agonist targeting the GIP, GLP-1, and glucagon receptors produced unprecedented weight loss in patients with type 2 diabetes after...